Organon drug linked with breast cancer

A common that treats the symptoms of menopause may lead to a recurrence of breast cancer in women who have previously had the disease, a new  study published in The Lancet Oncology has claimed.

Dutch drugmaker Organon's hormone therapy Livial (tibolone), was found  to be linked to the resurgence of breast cancer by a study funded by  Schering-Plough, which acquired Organon in 2007.

The trial, which recruited 3,098 women who had been treated for breast  cancer and were experiencing the symptoms of menopause, was originally  intended to compare the efficacy of tibolone to placebo. Instead, the  active cohort of the trial experienced a 15.2% incidence of breast  cancer recurrence, compared with 10.7% for the control group, an  increased risk of 40%.